Evidence map›Paper›PMID 39505788›Full record

ArticleDermatology and therapy2024

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study.

Ploysyne Rattanakaemakorn, Parawee Chevaisrakul, Chanisada Wongpraparut, Praveena Chiowchanwisawakit, Napatra Tovanabutra, Pimchanok Tantiwong, Warayuwadee Amornpinyo, Panlop Chakkavittumrong, Punchong Hanvivadhanakul, Sumapa Chaiamnuay and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ploysyne RattanakaemakornRamathibodi Hospital, Mahidol University, Bangkok, Thailand.
Parawee ChevaisrakulRamathibodi Hospital, Mahidol University, Bangkok, Thailand.
Chanisada WongpraparutSiriraj Hospital, Mahidol University, Bangkok, Thailand.
Praveena ChiowchanwisawakitSiriraj Hospital, Mahidol University, Bangkok, Thailand.
Napatra TovanabutraChiang Mai University, Chiang Mai, Thailand.
Pimchanok TantiwongKhon Kaen Hospital, Khon Kaen, Thailand.
Warayuwadee AmornpinyoKhon Kaen Hospital, Khon Kaen, Thailand.
Panlop ChakkavittumrongThammasat University, Pathum Thani, Thailand.
Punchong HanvivadhanakulThammasat University, Pathum Thani, Thailand.
Sumapa ChaiamnuayPhramongkutklao Hospital, Bangkok, Thailand.
Supapat LaodheerasiriPhramongkutklao Hospital, Bangkok, Thailand.
Bensachee PattamadilokInstitute of Dermatology, Bangkok, Thailand.
Charoen ChoonhakarnKhon Kaen University, Khon Kaen, Thailand.
Ajanee MahakkanukrauhKhon Kaen University, Khon Kaen, Thailand.
Duangkamol AiewruengsuratPrince of Songkla University, Songkla, Thailand.
Siripan SangmalaPrince of Songkla University, Songkla, Thailand.
Nisa PretikulMaharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand.
Kittiwan SumethkulRajavithi Hospital, Bangkok, Thailand.
Panchalee SatpanichVajira Hospital, Bangkok, Thailand.
Metavee BoonsiriVajira Hospital, Bangkok, Thailand.
Naruemon Sangob, Novartis, Thailand.
Pravit AsawanondaChulalongkorn University, Phayathai Road, Pathumwan, Bangkok, 10330, Thailand. fibrosis@gmail.com.ORCID http://orcid.org/0000-0002-2628-0894
PROMPT Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSecukinumab has proven to be effective and safe in psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in the phase 3 studies. However, data on real-world practice is limited.

methodsThis study is an ongoing, multicenter, 2-year observational study that focuses on patients with moderate to severe plaque PsO, active PsA, or AS receiving secukinumab. The aim of this study is to present baseline data for the entire study population.

resultsA total of 127 patients were enrolled, with 101 having PsO, 12 with PsA, and 14 with AS. Among the patients, approximately 54.0% were male. The mean body mass index ranged from 25.0 to 27.4 kg/m

conclusionThe study demonstrates disease durations, disease activity, and treatment history in Thai patients that were generally consistent with previous randomized controlled studies. Long-term data on the efficacy and safety of the treatment will be presented in future publications.

Indexed as

Axial spondyloarthritisPsoriasisPsoriatic arthritisSecukinumabThailand

Identifiers

PMID39505788
PMCPMC11604867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.